BCRX (BioCryst Pharmaceuticals) Cyclically Adjusted Revenue per Share: $1.42 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCRX BioCryst Pharmaceuticals Inc BCRX
70 GF Score
Price $9.85
GF Value $12.40
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share?

BioCryst Pharmaceuticals BCRX +1.55% 70 Cyclically Adjusted Revenue per Share is $1.42 as of Jun. 2026. GuruFocus rates BCRX with a GF Score™ of 70/100 and a GF Value™ of $12.40 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioCryst Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was $0.823. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.42 for the trailing ten years ended in Jun. 2026.

During the past 12 months, BioCryst Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 39.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 31.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 27.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioCryst Pharmaceuticals was 42.90% per year. The lowest was -23.20% per year. And the median was 3.75% per year.

As of today (2026-08-25), BioCryst Pharmaceuticals's current stock price is $9.85. BioCryst Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $1.42. BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 6.94.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioCryst Pharmaceuticals was 45.08. The lowest was 2.65. And the median was 8.64.


BioCryst Pharmaceuticals  (NAS:BCRX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9.85/1.42
=6.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioCryst Pharmaceuticals was 45.08. The lowest was 2.65. And the median was 8.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.55 0.70 0.91 1.25

BioCryst Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.02 1.07 1.25 1.33 1.42

BCRX vs PBH, SUPN, AMLX: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BCRX
70GF Score
BioCryst Pharmaceuticals Inc BCRX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioCryst Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.823/333.9520*333.9520
=0.823

Current CPI (Jun. 2026) = 333.9520.

BioCryst Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.105 241.428 0.145
201612 0.122 241.432 0.169
201703 0.126 243.801 0.173
201706 0.039 244.955 0.053
201709 0.105 246.819 0.142
201712 0.039 246.524 0.053
201803 0.040 249.554 0.054
201806 0.126 251.989 0.167
201809 0.014 252.439 0.019
201812 0.025 251.233 0.033
201903 0.053 254.202 0.070
201906 0.013 256.143 0.017
201909 0.016 256.759 0.021
201912 0.302 256.974 0.392
202003 0.031 258.115 0.040
202006 0.018 257.797 0.023
202009 0.035 260.280 0.045
202012 0.023 260.474 0.029
202103 0.107 264.877 0.135
202106 0.280 271.696 0.344
202109 0.229 274.310 0.279
202112 0.259 278.802 0.310
202203 0.270 287.504 0.314
202206 0.353 296.311 0.398
202209 0.407 296.808 0.458
202212 0.426 296.797 0.479
202303 0.365 301.836 0.404
202306 0.436 305.109 0.477
202309 0.457 307.789 0.496
202312 0.464 306.746 0.505
202403 0.450 312.332 0.481
202406 0.530 314.175 0.563
202409 0.566 315.301 0.599
202412 0.634 315.605 0.671
202503 0.676 319.799 0.706
202506 0.743 322.561 0.769
202509 0.725 324.800 0.745
202512 1.854 324.054 1.911
202603 0.646 330.213 0.653
202606 0.823 333.952 0.823

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.42 mean?
BioCryst Pharmaceuticals (BCRX) has a Cyclically Adjusted Revenue per Share of $1.42 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
BioCryst Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $1.42. Overall, BioCryst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to PBH and SUPN?
BioCryst Pharmaceuticals' Cyclically Adjusted Revenue per Share of $1.42 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.40, compared to a current price of $9.85 — trading 20.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.42. BioCryst Pharmaceuticals' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Cyclically Adjusted Revenue per Share is $1.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.85 is trading 20.6% below its estimated GF Value™ of $12.40. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • Cyclically Adjusted Revenue per Share: $1.42
  • GF Value™: $12.40 vs. price of $9.85 (20.6% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
70GF Score

Get the complete analysis for BCRX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.85
Price
$12.40
GF Value